LIS Technologies Inc

S-1 filed

Price $6.00 · Range $5.00 to $7.00 · 2,833,334 shares

LIS Technologies Inc. is advancing its uranium enrichment technology, with a focus on scaling up from laboratory to commercial operations. The company's development roadmap includes constructing a Pilot Plant and the LEU-3 Facility, both subject to significant risks. Key challenges include technical feasibility, regulatory approvals (notably from the NRC), securing financing, and supply chain reliability for critical materials like UF₆. The company emphasizes the uncertainty around timelines, production capacities, and market demand for its enrichment services.

DRS/A amended

LIS Technologies Inc's current DRS/A filing shows increased assets to $54.36M (from $37.75M) driven by higher cash reserves ($34.55M vs. $33.23M), property, plant & equipment ($17.01M vs. $2.03M), and in-process R&D ($1.68M vs. $1.24M). Liabilities rose to $17.73M (from $11.58M), with significant growth in acquisition consideration payable ($12.8M vs. $9.6M). The company reported a $9.17M net loss for the three months ended April 30, 2026, with continued operating losses and reliance on equity financing.

DRS filed

LIS Technologies Inc. is preparing for an IPO, as indicated by the DRS filing. The company's assets grew to $52.2M as of January 2026, driven by increased cash reserves and additional paid-in capital. Liabilities rose significantly, particularly the acquisition consideration payable in equity, which increased to $11.2M. The company continues to operate at a loss, reporting a $16.2M net loss in the three months ended January 2026, with accumulated losses totaling $51.95M as of that date. Financial statements highlight ongoing challenges in generating revenue and achieving profitability.